+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Provenge - Drug Insights, 2017

  • ID: 4038964
  • Drug Pipelines
  • 35 pages
  • DelveInsight
1 of 3
Drug Report, “Provenge - Drug Insights, 2017” highlights the Provenge marketed details, pipeline status and the Global API Manufacturers along with the location. The This report covers the Global Market Assessment of the Provenge covering the total sales estimation and also provides the Provenge sales performance during the historical period and forecast period to 2018. This report also covers the detailed clinical assessment of Provenge, patents information and exclusivity data, route of synthesis, competitive landscape, and generic players. In addition to this, This report provides the SWOT analysis for the Provenge.

Please note: This report requires certain updates. We have all the information available but require 2 business days to complete the process and ensure it is as up - to - date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.

Scope:
  • A review of the Provenge based on information derived from company and industry - specific sources
  • Coverage of the Marketed data of the Provenge on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
  • Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Provenge with location details
  • Patent Expiry Timeline and Exclusivity Details
  • Route of Synthesis of the API
  • Global Forecasted Sales Figure to 2018
  • Qualitative and quantitative assessment of market space
  • SWOT Analysis
Reasons to Buy:
  • Evaluate the marketing status and exclusivity details of Provenge to exploit opportunities for generic drug development opportunities.
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Provenge.
  • API intelligence over Provenge and gaining primary intelligence over Active Ingredients manufacturers across the globe.
  • Understanding the chemical route of synthesis of Provenge.
  • Uncovering opportunities in the rapidly growing the US market
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in - depth analysis of the drug’s performance
  • Obtain sales forecast for currently marketed drug for to 2018
Delivery Time: 2 Working Days.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction

2. Provenge Overview
2.1 Market Competition
2.3 Competitors in Development

3 Global Sales Assessment
3.1 Historical Sales of Provenge
3.2 Forecasted Sales of Provenge

4 Product Description
4.1 Mechanism of Action
4.2 Pharmacodynamic Properties
4.3 Pharmacokinetic Properties

5 Marketed Details
5.1 United States
5.2 Europe

6 Patent Information
6.1 Patent Numbers and Expiry Details
6.2 Patent and Exclusivity Expiry Assessment United States (US)
6.3 Patent Details

7 Route of Synthesis

8 Global API Manufacturers Assessment
8.1 The United States Drug Master File (US DMF)
8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China
8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India

9 Generic Players

10 The Pipeline Coverage

11 Clinical Trials Information
11.1 Clinical Trials by Zone

12 Company Profile
12.1 Company Summary
12.2 Company Financials

13 SWOT Analysis

14 References

15 Appendix

16 Methodology

17 Consulting Services

18 About Us

19 Contact Us

20 Disclaimer

List of Tables
Table 1: Provenge, Historical Global Sales (in million USD), 2017
Table 2: Provenge, Forecasted Global Sales (in million USD), 2017
Table 3: Provenge, Description
Table 4: Provenge, Marketed Details the United States (US)
Table 5: Provenge, Marketed Details the Europe (EU)
Table 6: Provenge, Patent/Exclusivity Expiry (Year), 2017
Table 7: Provenge, Patent Number Specific Patent Expiry (Year), 2017
Table 8: Provenge, Patent Details
Table 9: Provenge, Route of Synthesis
Table 10: Provenge, the United States Drug Master File (US DMF), 2017
Table 11: Provenge, the Europe Active Substance Master File (ASMF), 2017
Table 12: Provenge, the API Manufacturers, China, 2017
Table 13: Provenge, the API Manufacturers, India, 2017
Table 14: Provenge, Generic Players, 2017
Table 15: Provenge, Pipeline Drug Details, 2017
Table 16: Provenge, Clinical Trials, 2017
Table 17: Provenge, Clinical Trials by Zone, 2017
Table 18: Company Overview, 2017
Table 19: Provenge, SWOT Analysis, 2017

List of Figures
Figure 1: Provenge, Historical Global Sales (in million USD), 2017
Figure 2: Provenge, Forecasted Global Sales (in million USD), 2017
Figure 3: Provenge, Patent/Exclusivity Expiry (Year), 2017
Figure 4: Provenge, Patent Number Specific Patent Expiry (Year), 2017
Figure 5: Provenge, Route of synthesis
Figure 6: Provenge, the API Manufacturers by the US DMF Status (%), 2017
Figure 7: Provenge, the API Manufacturers by Region, 2017
Figure 8: Provenge, the API Manufacturers by Location/Countries, 2017
Figure 9: Provenge, Generic Players, 2017
Figure 10: Provenge, Clinical Trials by Zone (%), 2017
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4038964
Adroll
adroll